(Q43008115)

English

Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma

scientific article published on October 2010

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

systemic therapy

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

object named as

Chih-Hung Hsu

5

0 references

object named as

Yu-Yun Shao

1

0 references

author name string

Zhong-Zhe Lin

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Chiun Hsu

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Ying-Chun Shen

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

language of work or name

0 references

publication date

1 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

116

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

4590-4596

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular targeted therapies in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical trials in primary hepatocellular carcinoma: current status and future directions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

Postoperative detection of alpha-fetoprotein mRNA in blood as a predictor for metastatic recurrence of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

alpha-Fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: a prospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

The anti-angiogenic basis of metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular and cellular biomarkers for angiogenesis in clinical oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25257

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.25257

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43008115&oldid=1976521722"